MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202611000685 A) filed by Garima Chauhan; Dr. Sahil Kumar; Dr. D. P. Pathak; Pragya Dubey; Deepak Kumar; and Md. Azhar Iqbal, New Delhi, on Jan. 4, for 'novel quinazolinone-benzoxazolinone and phthalimide hybrids as potent vegfr-2 inhibitors for breast cancer therapy.'
Inventor(s) include Garima Chauhan; Dr. Sahil Kumar; Dr. D. P. Pathak; Pragya Dubey; Deepak Kumar; and Md. Azhar Iqbal.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to novel quinazoline/quinazolinone-based hybrid compounds useful as anticancer agents for the treatment of breast cancer. The disclosed compounds comprise a quinazoline or quinazolinone nucleus chemically linked with a nitrogen-containing heterocyclic moiety selected from benzoxazolinone or phthalimide, thereby forming structurally distinct hybrid molecules. The synthesized hybrid compounds exhibit significant anticancer activity against breast cancer cell lines, including the MCF-7 cell line, as evaluated by standard in-vitro cytotoxicity assays, with comparative assessment against the reference anticancer drug Sorafenib. Molecular docking studies further support the interaction of selected hybrid compounds with vascular endothelial growth factor receptor-2 (VEGFR-2), demonstrating favorable binding affinity and interaction profiles, as evidenced using the VEGFR-2 crystal structure (PDB ID: 4AGD). The disclosed compounds are useful in inhibiting the growth of breast cancer cells and provide new molecular entities for anticancer treatment."
Disclaimer: Curated by HT Syndication.
